Pernix Therapeutics to Report Third Quarter 2013 Financial Results on November 12, 2013 Management to Host a Conference Call on November 12, 2013 at 9:00 a.m. EDT Business Wire HOUSTON -- October 24, 2013 Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its third quarter 2013 financial results before the U.S. stock market opens on Tuesday, November 12, 2013 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results. The conference call will feature remarks by Michael Pearce, Chairman of the Board, President, and Chief Executive Officer, and Tracy Clifford, Principal Accounting Officer. To participate in the conference call, please dial (877) 312-8783 (domestic) or (408) 940-3874 (international). Participants can reference the passcode 75172136. Please dial in approximately 5 minutes prior to the call. The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website www.pernixtx.com. The passcode is 75172136. Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast. A replay of the conference call will be available through November 19, 2013, at (855) 859-2056 domestic and (404) 537-3406 international. The passcode for the replay is 75172136. An online archive of the webcast will be available on the Company’s website for 30 days following the call. About Pernix Therapeutics Holdings, Inc. Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under a co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary management. The Company also markets the branded product, SILENOR®, for the treatment of insomnia. The Company promotes its branded pediatric and gastroenterology products through its sales force. Pernix markets its generic products through its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage-forms. Additional information about Pernix is available on the Company’s website located at www.pernixtx.com. Contact: Pernix Therapeutics Holdings, Inc. Michael C. Pearce, 843-654-7720 Ext. 7407 President and CEO email@example.com
Pernix Therapeutics to Report Third Quarter 2013 Financial Results on November 12, 2013
Press spacebar to pause and continue. Press esc to stop.